About us

Quantifying the CML treatment market: Assessing physician insights and market share of major treatments.

The project quantifies CML treatment demand and explains the prescribing decisions behind market share. It directs commercial investment toward patient segments and treatment lines where clinical differentiation and access conditions create realistic opportunities to gain or defend share.

Outcome

  • Validated estimates of treated patient populations and product shares, distinguishing established treatment use from new patient starts and switching.
  • Clear understanding of why haematologists select, continue or change therapies, linking prescribing patterns to clinical priorities and access conditions.
  • Prioritized growth opportunities by patient segment and treatment line, grounded in unmet needs and the client’s competitive position.
  • Defined positioning and prescriber engagement priorities, supported by a clearer view of addressable demand and barriers to adoption.

KEY INTELLIGENCE OBJECTIVES

  • Estimate diagnosed and actively treated CML populations by disease phase and treatment line, distinguishing patients receiving medication from those in supervised treatment-free remission.
  • Quantify market share by molecule and brand, separating shares among existing patients, newly initiated patients, and those switching treatment.
  • Map treatment sequencing across imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib, reflecting locally approved indications and funded access.
  • Assess physician selection criteria, including molecular response, tolerability, comorbidities, patient preferences, and treatment goals, identifying where prescribing habits differ between centres.
  • Analyze how molecular monitoring, resistance testing, and follow-up assessments influence dose adjustments, treatment continuation, and switching to another medicine.
  • Benchmark physician perceptions of competing treatments, identifying which clinical advantages influence actual prescribing, and where familiarity or established practice limits adoption.
  • Examine reimbursement, formulary access, pricing, and generic availability, assessing their effects on product selection and the relationship between patient share and market value.
  • Validate physician-reported market estimates against epidemiological and treatment data, accounting for differences in center size, patient mix, and referral concentration.

Geography

  • Europe
  • Middle East
  • Africa
  • North America
  • Latin America
  • Asia-Pacific
  • Global

    • Go back to our case studies

    Get the report

    SUBSCRIBE TO MARKET MINDS

    What matters now. Subscribe to receive intelligence that helps you act before others do.

    Contact us

    Let’s start with a conversation.
    Tell us what you’re facing.

    EMBS GROUP Sp. z o.o. Sp. k., as the Data Administrator, will process the personal data provided above to respond to the message sent via the form. You can contact us at gdpr@embs-group.com or our registered office (Poland, 30-224 Kraków, Aleja Sosnowa 2a).
    The full text of the information clause is available in the Privacy Policy.
    Privacy Overview

    EMBS Group, as the Data Administrator, uses cookies to enhance user experience and analyze website traffic. You can change your cookie settings at any time. For more information, please see our Privacy Policy.